Pulling the plug on a cancer cell by eliminating XIAP with AEG35156

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 215-224

  LaCasse, Eric C ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

AEG35156; Antisense; Apoptosis; Cancer therapy; Clinical trials; IAP; XIAP

Indexed keywords

AEG 35156; CYTARABINE; DRISAPERSEN; GEMCITABINE; IDARUBICIN; MIPOMERSEN; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASCITES; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; INFUSION RELATED REACTION; LIVER TOXICITY; LOADING DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METABOLIC ACIDOSIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT INDICATION; TUMOR IMMUNITY;

EID: 84876071466     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.06.015     Document Type: Review

References (79)

1. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259.
2. Wright M.E., Han D.K., Hockenbery D.M. Caspase-3 and inhibitor of apoptosis protein(s) interactions in Saccharomyces cerevisiae and mammalian cells. FEBS Lett. 2000, 481:13-18.
3. Eckelman B.P., Salvesen G.S., Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006, 7:988-994.
4. Owens T.W., Foster F.M., Valentijn A., Gilmore A.P., Streuli C.H. Role for X-linked Inhibitor of apoptosis protein upstream of mitochondrial permeabilization. J. Biol. Chem. 2010, 285:1081-1088.
5. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nature Rev. Cancer 2010, 10:561-574.
6. Wu Z.H., Wong E.T., Shi Y., Niu J., Chen Z., Miyamoto S., Tergaonkar V. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 2010, 40:75-86.
7. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nature Rev. Drug Discov. 2012, 11:109-124.
8. Potts P.R., Singh S., Knezek M., Thompson C.B., Deshmukh M. Critical function of endogenous XIAP in regulating caspase activation during sympathetic neuronal apoptosis. J. Cell Biol. 2003, 163:789-799.
9. Mehrotra S., Languino L.R., Raskett C.M., Mercurio A.M., Dohi T., Altieri D.C. IAP regulation of metastasis. Cancer Cell 2010, 17:53-64.
10. Dogan T., Harms G.S., Hekman M., Karreman C., Oberoi T.K., Alnemri E.S., Rapp U.R., Rajalingam K. X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nature Cell Biol. 2008, 10:1447-1455.
11. Oberoi T.K., Dogan T., Hocking J.C., Scholz R.P., Mooz J., Anderson C.L., Karreman C., Meyer zu Heringdorf D., Schmidt G., Ruonala M., Namikawa K., Harms G.S., Carpy A., Macek B., Köster R.W., Rajalingam K. IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J. 2011, 31:14-28.
12. Liu J., Zhang D., Luo W., Yu Y., Yu J., Li J., Zhang X., Zhang B., Chen J., Wu X.R., Rosas-Acosta G., Huang C. X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. J. Biol. Chem. 2011, 286:15630-15640.
13. Tenev T., Bianchi K., Darding M., Broemer M., Langlais C., Wallberg F., Zachariou A., Lopez J., MacFarlane M., Cain K., Meier P. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 2011, 43:432-448.
14. S.T. Beug, H.C. Cheung, E.C. LaCasse, R.G. Korneluk, Modulation of immune signaling by inhibitors of apoptosis. Trends Immunol, in press.
15. Kreuzaler P., Watson C.J. Killing a cancer: what are the alternatives?. Nat. Rev. Cancer. 2012, 12:411-424.
16. Lu M., Lin S.C., Huang Y., Kang Y.J., Rich R., Lo Y.C., Myszka D., Han J., Wu H. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol. Cell. 2007, 26:689-702.
17. Neil J.R., Tian M., Schiemann W.P. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J. Biol. Chem. 2009, 284:21209-21217.
18. Rehm M., Huber H.J., Dussmann H., Prehn J.H. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J. 2006, 25:4338-4349.
19. Albeck J.G., Burke J.M., Aldridge B.B., Zhang M., Lauffenburger D.A., Sorger P.K. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol. Cell 2008, 30:11-25.
20. Harlin H., Reffey S.B., Duckett C.S., Lindsten T., Thompson C.B. Characterization of XIAP-deficient mice. Mol. Cell. Biol. 2001, 21:3604-3608.
21. Olayioye M.A., Kaufmann H., Pakusch M., Vaux D.L., Lindeman G.J., Visvader J.E. XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland. Cell Death Differ. 2005, 12:87-90.
22. Rigaud S., Fondanèche M.C., Lambert N., Pasquier B., Mateo V., Soulas P., Galicier L., Le Deist F., Rieux-Laucat F., Revy P., Fischer A., de Saint Basile G., Latour S. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006, 444:110-114.
23. Rumble J.M., Oetjen K.A., Stein P.L., Schwartzberg P.L., Moore B.B., Duckett C.S. Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP). Cell. Immunol. 2009, 259:82-89.
24. Marsh R.A., Madden L., Kitchen B.J., Mody R., McClimon B., Jordan M.B., Bleesing J.J., Zhang K., Filipovich A.H. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010, 116:1079-1082.
25. Pachlopnik Schmid J., Canioni D., Moshous D., Touzot F., Mahlaoui N., Hauck F., Kanegane H., Lopez-Granados E., Mejstrikova E., Pellier I., Galicier L., Galambrun C., Barlogis V., Bordigoni P., Fourmaintraux A., Hamidou M., Dabadie A., Le Deist F., Haerynck F., Ouachée-Chardin M., Rohrlich P., Stephan J.L., Lenoir C., Rigaud S., Lambert N., Milili M., Schiff C., Chapel H., Picard C., de Saint Basile G., Blanche S., Fischer A., Latour S. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117:1522-1529.
26. Goping I.S., Barry M., Liston P., Sawchuk T., Constantinescu G., Michalak K.M., Shostak I., Roberts D.L., Hunter A.M., Korneluk R., Bleackley R.C. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity 2003, 18:355-365.
27. Jost P.J., Grabow S., Gray D., McKenzie M.D., Nachbur U., Huang D.C., Bouillet P., Thomas H.E., Borner C., Silke J., Strasser A., Kaufmann T. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009, 460:1035-1039.
28. Cummins J.M., Kohli M., Rago C., Kinzler K.W., Vogelstein B., Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 2004, 64:3006-3008.
29. Conte D., Liston P., Wong J.W., Wright K.E., Korneluk R.G. Thymocyte-targeted overexpression of xiap transgene disrupts T lymphoid apoptosis and maturation. Proc. Natl. Acad. Sci. USA 2001, 98:5049-5054.
30. Ravi R., Fuchs E.J., Jain A., Pham V., Yoshimura K., Prouser T., Jalla S., Zhou X., Garrett-Mayer E., Kaufmann S.H., Schulick R.D., Pardoll D.M., Bedi A. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res. 2006, 66:1730-1739.
31. Zehntner S.P., Bourbonnière L., Moore C.S., Morris S.J., Methot D., St Jean M., Lacasse E., Hebb A.L., Robertson G.S., Durkin J., Gillard J.W., Owens T. X-linked inhibitor of apoptosis regulates T cell effector function. J. Immunol. 2007, 179:7553-7560.
32. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
33. Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin. Cancer Res. 2010, 16:4496-4502.
34. Yang L., Cao Z., Yan H., Wood W.C. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res. 2003, 63:6815-6824.
35. Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., Marusawa H., Zou H., Armstrong R., Matsuzawa S., Salvesen G.S., Reed J.C., Altieri D.C. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 2004, 279:34087-34090.
36. Yan Y., Mahotka C., Heikaus S., Shibata T., Wethkamp N., Liebmann J., Suschek C.V., Guo Y., Gabbert H.E., Gerharz C.D., Ramp U. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Brit. J. Cancer 2004, 91:1349-1357.
37. Qin S., Yang C., Li S., Xu C., Zhao Y., Ren H. Smac: its role in apoptosis induction and use in lung cancer diagnosis and treatment. Cancer Lett. 2012, 318:9-13.
38. Liston P., Fong W.G., Kelly N.L., Toji S., Miyazaki T., Conte D., Tamai K., Craig C.G., McBurney M.W., Korneluk R.G. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nature Cell Biol. 2001, 3:128-133.
39. Huang J., Yao W.Y., Zhu Q., Tu S.P., Yuan F., Wang H.F., Zhang Y.P., Yuan Y.Z. XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer. Cancer Sci. 2010, 101:559-567.
40. Kempkensteffen C., Fritzsche F.R., Johannsen M., Weikert S., Hinz S., Dietel M., Riener M.O., Moch H., Jung K., Krause H., Miller K., Kristiansen G. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer 2009, 9:276.
41. García-Cao I., Duran A., Collado M., Carrascosa M.J., Martín-Caballero J., Flores J.M., Diaz-Meco M.T., Moscat J., Serrano M. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep. 2005, 6:577-583.
42. Liwak U., Thakor N., Jordan L.E., Roy R., Lewis S.M., Pardo O.E., Seckl M., Holcik M. Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2. Mol. Cell. Biol. 2012, 32:1818-1829.
43. García-Fernández M., Kissel H., Brown S., Gorenc T., Schile A.J., Rafii S., Larisch S., Steller H. Sept4/ARTS is required for stem cell apoptosis and tumor suppression. Genes Dev. 2010, 24:2282-2293.
44. Garrison J.B., Correa R.G., Gerlic M., Yip K.W., Krieg A., Tamble C.M., Shi R., Welsh K., Duggineni S., Huang Z., Ren K., Du C., Reed J.C. ARTS and Siah collaborate in a pathway for XIAP degradation. Mol. Cell 2011, 41:107-116.
45. Schile A.J., García-Fernández M., Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev. 2008, 22:2256-2266.
46. Gu L., Zhu N., Zhang H., Durden D.L., Feng Y., Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 2009, 15:363-375.
47. Lu J., Bai L., Sun H., Nikolovska-Coleska Z., McEachern D., Qiu S., Miller R.S., Yi H., Shangary S., Sun Y., Meagher J.L., Stuckey J.A., Wang S. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008, 68:9384-9393.
48. Ndubaku C., Varfolomeev E., Wang L., Zobel K., Lau K., Elliott L.O., Maurer B., Fedorova A.V., Dynek J.N., Koehler M., Hymowitz S.G., Tsui V., Deshayes K., Fairbrother W.J., Flygare J.A., Vucic D. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 2009, 4:557-566.
49. Hybridon and Aegera collaborate to develop antisense drug, Expert Rev. Anticancer Ther. 2 (2002) 483-484 (No authors listed).
50. Lacasse E.C., Kandimalla E.R., Winocour P., Sullivan T., Agrawal S., Gillard J.W., Durkin J. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/GEM640. Ann. NY Acad. Sci. 2005, 1058:215-234.
51. McManus D.C., Lefebvre C.A., Cherton-Horvat G., St-Jean M., Kandimalla E.R., Agrawal S., Morris S.J., Durkin J.P., Lacasse E.C. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23:8105-8117.
52. LaCasse E.C., Cherton-Horvat G.G., Hewitt K.E., Jerome L.J., Morris S.J., Kandimalla E.R., Yu D., Wang H., Wang W., Zhang R., Agrawal S., Gillard J.W., Durkin J.P. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. 2006, 12:5231-5241.
53. Shaw T.J., Lacasse E.C., Durkin J.P., Vanderhyden B.C. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int. J. Cancer 2008, 122:1430-1434.
54. Carter B.Z., Mak D.H., Morris S.J., Borthakur G., Estey E., Byrd A.L., Konopleva M., Kantarjian H., Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2011, 16:67-74.
55. Holt S.V., Brookes K.E., Dive C., Makin G.W. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol. Rep. 2011, 25:1177-1181.
56. Eschenburg G., Eggert A., Schramm A., Lode H.N., Hundsdoerfer P. Smac MImetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis. Cancer Res. 2012, 72:2645-2656.
57. Farman C.A., Kornbrust D.J. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol. Pathol. 2003, 31(Suppl):119-122.
58. Dean E., Jodrell D., Connolly K., Danson S., Jolivet J., Durkin J., Morris S., Jowle D., Ward T., Cummings J., Dickinson G., Aarons L., Lacasse E., Robson L., Dive C., Ranson M. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J. Clin. Oncol. 2009, 27:1660-1666.
59. Schimmer A.D., Estey E.H., Borthakur G., Carter B.Z., Schiller G.J., Tallman M.S., Altman J.K., Karp J.E., Kassis J., Hedley D.W., Brandwein J., Xu W., Mak D.H., LaCasse E., Jacob C., Morris S.J., Jolivet J., Andreeff M. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J. Clin. Oncol. 2009, 27:4741-4746.
60. Schimmer A.D., Herr W., Hänel M., Borthakur G., Frankel A., Horst H.A., Martin S., Kassis J., Desjardins P., Seiter K., Fiedler W., Noppeney R., Giagounidis A., Jacob C., Jolivet J., Tallman M.S., Koschmieder S. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin. Lymphoma Myeloma Leuk. 2011, 11:433-438.
61. Mahadevan D., Chalasani P., Rensvold D., Kurtin S., Pretzinger C., Jolivet J., Ramanathan R.K., Von Hoff D.D., Weiss G.J. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am. J. Clin. Oncol. 2012, (Epub ahead of print).
62. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., Lachmann R.H., Gaudet D., Tan J.L., Chasan-Taber S., Tribble D.L., Flaim J.D., Crooke S.T. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
63. Visser M.E., Witztum J.L., Stroes E.S., Kastelein J.J. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 2012, 33:1451-1458.
64. Mufti A.R., Burstein E., Csomos R.A., Graf P.C., Wilkinson J.C., Dick R.D., Challa M., Son J.K., Bratton S.B., Su G.L., Brewer G.J., Jakob U., Duckett C.S. XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol. Cell 2006, 21:775-785.
65. Weiss K.H., Runz H., Noe B., Gotthardt D.N., Merle U., Ferenci P., Stremmel W., Füllekrug J. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J. Inherit. Metab. Dis. 2010, (Epub ahead of print).
66. Burstein E., Ganesh L., Dick R.D., van De Sluis B., Wilkinson J.C., Klomp L.W., Wijmenga C., Brewer G.J., Nabel G.J., Duckett C.S. A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J. 2004, 23:244-254.
67. Rena Hesse A., Hagemeier K., Lürbke A., Held J., Friedman H., Peterson A., Brück W., Kuhlmann T. XIAP protects oligodendrocytes against cell death in vitro but has no functional role in toxic demyelination. Glia 2012, 60:271-280.
68. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., Sausville E.A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Brit. J. Cancer 2001, 84:1424-1431.
69. Foster F.M., Owens T.W., Tanianis-Hughes J., Clarke R.B., Brennan K., Bundred N.J., Streuli C.H. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 2009, 11:R41.
70. Aird K.M., Ghanayem R.B., Peplinski S., Lyerly H.K., Devi G.R. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol. Cancer Ther. 2010, 9:1432-1442.
71. Spencer S.L., Gaudet S., Albeck J.G., Burke J.M., Sorger P.K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009, 459:428-432.
72. Sensintaffar J., Scott F.L., Peach R., Hager J.H. XIAP is not required for human tumor cell survival in the absence of an exogenous death signal. BMC Cancer 2010, 10:11.
73. Stadel D., Mohr A., Ref C., MacFarlane M., Zhou S., Humphreys R., Bachem M., Cohen G., Möller P., Zwacka R.M., Debatin K.M., Fulda S. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin. Cancer Res. 2010, 16:5734-5749.
74. Maas C., Verbrugge I., de Vries E., Savich G., van de Kooij L.W., Tait S.W., Borst J. Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation. Cell Death Differ. 2010, 17:1613-1623.
75. Li X.B., Jiao S., Sun H., Xue J., Zhao W.T., Fan L., Wu G.H., Fang J. The orphan nuclear receptor EAR2 is overexpressed in colorectal cancer and it regulates survivability of colon cancer cells. Cancer Lett. 2011, 309:137-144.
76. Seeger J.M., Brinkmann K., Yazdanpanah B., Haubert D., Pongratz C., Coutelle O., Krönke M., Kashkar H. Elevated XIAP expression alone does not confer chemoresistance. Brit. J. Cancer 2010, 102:1717-1723.
77. Jones D. The long march of antisense. Nature Rev. Drug Discov. 2011, 10:401-402.
78. Goemans N.M., Tulinius M., van den Akker J.T., Burm B.E., Ekhart P.F., Heuvelmans N., Holling T., Janson A.A., Platenburg G.J., Sipkens J.A., Sitsen J.M., Aartsma-Rus A., van Ommen G.J., Buyse G., Darin N., Verschuuren J.J., Campion G.V., de Kimpe S.J., van Deutekom J.C. Systemic administration of PRO051 in Duchenne's muscular dystrophy. Engl. J. Med. 2011, 364:1513-1522.
79. Nakamura T., Wang L., Wong C.C., Scott F.L., Eckelman B.P., Han X., Tzitzilonis C., Meng F., Gu Z., Holland E.A., Clemente A.T., Okamoto S., Salvesen G.S., Riek R., Yates J.R., Lipton S.A. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol. Cell 2010, 39:184-195.